Charles Cleeland

Source: faculty.mdanderson.org

Charles S. Cleeland, Ph.D., was a panel member and contributed his expertise to the February 2015, Institute of Medicine report, Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Redefining an Illness.

The following biographical sketch is from Appendix E of the Institute of Medicine report, Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness.

"Charles S. Cleeland, Ph.D., is a McCullough professor of cancer research and chair, Department of Symptom Research, at the University of Texas MD Anderson Cancer Center. He is a leader in the area of cancer symptom epidemiology, assessment, and treatment. He has directed epidemiological studies of pain and other symptoms in patients with cancer; studies of the mechanisms of pain and other symptoms; studies using positron emission tomography (PET) and functional magnetic resonance imaging (fMRI) to examine the effects of pain on cortical activity; and clinical trials aimed at reducing the risk of inadequate symptom control, including in underserved populations. Dr. Cleeland is a member and past president of the board of directors of the U.S. Cancer Pain Relief Committee. He is also past president of the American Pain Society. His research is widely published. He has published numerous studies on the prevalence and severity of cancer symptoms, on U.S. and international symptom management practice patterns, and on potential biological mechanisms underlying the symptoms produced by cancer and its treatment."

Education

• NIH Postdoctoral Fellow - Neurology, University of Wisconsin, Madison, WI
• PHD - Washington University, St. Louis, MO, Clinical Psychology
• BA - Wesleyan University, Middletown, CT, with honors, Psychology

Awards

• 2000 Distinguished Service Award, American Pain Society
• 2002 Fordyce Clinical Investigator Award, American Pain Society
• 2007 Trish Greene Quality of Life Award, American Cancer Society
• 2008 30th Annual Dr. John J. Bonica Award, Eastern Pain Association
• 2009 Award for Excellence in Contributions to the Committee for Rehabilitation and Palliative Care, The Chinese Anti-Cancer Association
• 2010 Raymond Houde Award and Lecture, Eastern Pain Society

See also

• Faculty page for MD Anderson Cancer Center, The University of Texas

myalgic encephalomyelitis (M.E.) - A disease often marked by neurological symptoms, but fatigue is sometimes a symptom as well. Some diagnostic criteria distinguish it from chronic fatigue syndrome, while other diagnostic criteria consider it to be a synonym for chronic fatigue syndrome. A defining characteristic of ME is post-exertional malaise (PEM), or post-exertional neuroimmune exhaustion (PENE), which is a notable exacerbation of symptoms brought on by small exertions. PEM can last for days or weeks. Symptoms can include cognitive impairments, muscle pain (myalgia), trouble remaining upright (orthostatic intolerance), sleep abnormalities, and gastro-intestinal impairments, among others. An estimated 25% of those suffering from ME are housebound or bedbound. The World Health Organization (WHO) classifies ME as a neurological disease.

See National Institutes of Health.

National Institutes of Health (NIH) - A set of biomedical research institutes operated by the U.S. government, under the auspices of the Department of Health and Human Services.